



## **Michael Gausling New OraSure Technologies CEO**

January 31, 2002

BETHLEHEM, Pa., Jan 31, 2002 (BW HealthWire) -- OraSure Technologies, Inc. (Nasdaq NM:OSUR), the market leader in oral fluid diagnostics, appointed Michael Gausling as Chief Executive Officer.

He replaces Robert D. Thompson who resigned his positions as CEO and a member of OraSure's Board of Directors to pursue other opportunities.

In addition to being named CEO, Mr. Gausling will continue as President and a member of OraSure's Board of Directors. Mr. Gausling was a Founder and CEO of STC Technologies, which merged with Epiteo, Inc. in September 2000 to form OraSure Technologies.

Mike Gausling stated, "I have enjoyed working with Bob Thompson and wish him well in his future endeavors. We have combined the best of both companies into a dynamic organization. The management team is dedicated to continuing to build on our leadership position in oral fluid diagnostics by realizing the full potential of our new products, Intercept(R), OraQuick(R) and UPLink(TM)."

### **Important Information**

This press release contains certain forward-looking statements with respect to revenues, earnings, and markets. Actual results could be significantly different.

Factors that could affect results include the ability to market products; impact of competitors, competing products and technology changes; ability to develop, commercialize and market new products; market acceptance of oral fluid testing products and up-converting phosphor technology products; ability to fund research and development and other projects and operations; ability to obtain and timing of obtaining necessary regulatory approvals; ability to develop product distribution channels; uncertainty relating to patent protection and potential patent infringement claims; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally; loss or impairment of sources of capital; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; changes in relationships with strategic partners and reliance on strategic partners for the performance of critical activities under collaborative arrangements; changes in accounting practices or interpretation of accounting requirements; equipment failures and ability to obtain needed raw materials and components; and general business and economic conditions.

These and other factors are discussed more fully in the Securities and Exchange Commission filings of OraSure Technologies, including its Annual Report on Form 10-K for the year ended December 31, 2000, and most recent Quarterly Report on Form 10-Q.

Although forward-looking statements help to provide complete information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

### **About OraSure Technologies**

OraSure Technologies, Inc. is the market leader for oral fluid diagnostics. The Company develops, manufactures, and markets medical devices and diagnostic products for use by insurance companies, public health agencies, clinical laboratories, physicians' offices, and workplace sites.

For more information on the Company, please visit [www.orasure.com](http://www.orasure.com).

CONTACT: OraSure Technologies  
Ronald H. Spair, 610/882-1820  
[Investorinfo@orasure.com](mailto:Investorinfo@orasure.com)

Copyright (C) 2002 Business Wire. All rights reserved.